摘要
目的观察长春瑞滨联合顺铂（NP组）与紫杉醇联合顺铂（TP组）治疗晚期肺腺癌的疗效及毒副反应。方法将80例经病理或细胞学证实的晚期肺腺癌患者,分为两组,NP组44例,TP组36例。NP组：长春瑞滨25 mg/m2,静脉推注,第1、8天;顺铂（DDP）25 mg/m2,静脉点滴,第1~3天,每21天为1个周期。TP组：紫杉醇135~175 mg/m2,静脉滴注,第1天,持续3~4 h;顺铂用法同上,每21天为1个周期。连用2个周期以上。结果 NP组总有效率[完全缓解（CR）＋部分缓解（PR）]为40.9%,1年生存率36.4%;TP组总有效率为44.4%,1年生存率为41.7%,两组间总有效率和1年生存率比较均差异无统计学意义（P〉0.05）。最常见的毒副反应是骨髓抑制和胃肠道反应,骨髓抑制两组间比较差异有统计学意义（P〈0.05）,NP组骨髓抑制较TP组重,胃肠道反应两组间比较差异无统计学意义（P〉0.05）。结论紫杉醇联合顺铂的骨髓抑制毒副反应明显小于长春瑞滨联合顺铂。
Objective To compare the efficacy and toxicity of vinorelbine plus cisplatin（NP） and paclitaxel plus cisplatin（TP） in the treatment of advanced lung adenocarinoma.Methods 80 patients with advanced lung adenocarcinoma were administrated vinorelbine 25 mg/m^2 on 1 d,8 d by intravenous infusion and cisplatin 25 mg/m^2 from 1 d to 3 d（group NP,44 patients）,or paclitaxel 135-175 mg/m^2 on 1 d by intravenous infusion and cisplatin 25 mg/m^2 for 3-4 h from 1 d to 3 d（group TP,36 patients）.Both regimens were repeated every 3 weeks.Results The objective response rate of 50% was observed in NP group versus 25% in TP group（P〉0.05）.The 1-year survival rate was 36% in NP group and 33% in TP group（P〉0.05）.The major toxicity included neutropenia（P〈0.05）,nausea and vomiting（P〉0.05）.Conclusion Vinorelbine plus cisplatin（NP） and paclitaxel plus cisplatin（TP） are safe and effective therapy for advanced lung adenocarinoma.The toxicity of TP is much lower than that of NP.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第17期2348-2349,共2页
Chongqing medicine
关键词
长春瑞滨
紫杉醇
顺铂
肺腺癌
化疗
vinorelbine
paclitaxel
cisplatin
lung adenocarcinoma
drug therapy
